VJHemOnc is committed to improving our service to you

ASH 2019 | Exciting results for BCMA/CD3 bispecific PF-3135 in R/R MM

VJHemOnc is committed to improving our service to you

Noopur Raje

PF-06863135 (PF-3135) is a bispecific, humanized, monoclonal antibody consisting of BCMA and CD3-targeting arms paired on an IgG2a backbone by hinge-mutation technology. Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, discusses the dose-escalation portion of an ongoing phase I study (NCT03269136) of PF-3135 in patients with relapsed/refractory multiple myeloma (MM). Early data show that treatment with intravenous PF-3135 was well tolerated at the dose levels evaluated. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter